Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women [1]

HIV Clinical Trials

Volumn 8, Issue 4, 2007, Pages 254-255

  Khuong Josses, Marie Aude ^a   Azerad, David ^a   Boussaïri, Abdelghani ^a   Ekoukou, Dieudonné ^a  

^a DELAFONTAINE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR; RITONAVIR; ZIDOVUDINE;

ADULT; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MONITORING; FEMALE; FOLLOW UP; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; PREGNANCY; PRIORITY JOURNAL; TABLET; VIRUS LOAD;

ADULT; CAPSULES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIMIDINONES; TABLETS;

EID: 34548237586     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0804-254     Document Type: Letter

References (5)

1. French HIV therapy guidelines, 2006. Available at: http://www.sante.gouv. fr/htm/actu/yeni_sida/rapport_experts_2006.pdf. Accessed March 21, 2007.
2. Stek A, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. In: Program and abstracts of the XVth International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract LbOrB08.
3. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS. 2007;21:643-647.
4. Mirochnik M, Stek A, Capparelli E, et al. Adequate lopinavir exposure achieved with higher dose during the third trimester of pregnancy. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colorado. Abstract 710.
5. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailibility to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminushed food effect. J Acquir Immune Defic Syndr. 2007;44:401-410.